Company news
Mustang Bio, Inc. news in 2020
Mustang Bio, Inc.'s news releases, calls and decks from 2020, newest first.
Mustang Bio and City of Hope Announce Initiation of Phase 1 Clinical Trial of MB-101 (IL13Rα2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors
December 20, 2020
Mustang Bio Announces Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
December 6, 2020
Mustang Bio to Host Key Opinion Leader Call on MB-106 for the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
November 30, 2020
Mustang Bio Announces Positive Opinion from the European Medicines Agency on Orphan Drug Designation for Its Lentiviral Gene Therapy for the Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”)
November 23, 2020
Mustang Bio and Minaris Regenerative Medicine Sign Technology Transfer and GMP Manufacturing Agreement for MB-107 Lentiviral Gene Therapy for X-Linked Severe Combined Immunodeficiency
November 22, 2020
Mustang Bio Reports Third Quarter 2020 Financial Results and Recent Corporate Highlights
November 5, 2020
Mustang Bio Announces MB-106 Data Selected for Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting
November 3, 2020
Mustang Bio Announces Initial Phase 1 Data on MB-105 for Patients with PSCA-positive Castration Resistant Prostate Cancer
October 25, 2020
Mustang Bio Announces MB-105 Data Selected for Presentation at the Virtual 27th Annual Prostate Cancer Foundation Scientific Retreat
October 7, 2020
Mustang Bio Licenses LentiBOOST™ Technology from SIRION Biotech
October 5, 2020
Mustang Bio Announces First Patient Dosed in Multicenter Phase 1/2 Clinical Trial of MB-102 (CD123-targeted CAR T Cell Therapy)
September 30, 2020
Mustang Bio Announces Orphan Drug Designation for MB-207 for the Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”) in Previously Transplanted Patients
September 21, 2020
Mustang Bio Announces Orphan Drug Designation for MB-107 for the Treatment of X-linked Severe Combined Immunodeficiency in Newly Diagnosed Infants
September 1, 2020
Mustang Bio Announces Rare Pediatric Disease Designation for MB-207 for the Treatment of X-linked Severe Combined Immunodeficiency in Previously Transplanted Patients
August 30, 2020
Mustang Bio Announces Rare Pediatric Disease Designation for MB-107 for the Treatment of X-linked Severe Combined Immunodeficiency
August 16, 2020
Mustang Bio Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights
August 9, 2020
Mustang Bio Announces Pricing of Public Offering of Common Stock
June 10, 2020
Mustang Bio Announces Proposed Public Offering of Common Stock
June 9, 2020
Mustang Bio to Host Virtual Annual Meeting of Stockholders
June 3, 2020
Mustang Bio Announces Presentations at 23rd Annual Meeting of the American Society of Gene & Cell Therapy
May 11, 2020
Mustang Bio Reports First Quarter 2020 Financial Results and Recent Corporate Highlights
May 10, 2020
Mustang Bio Receives Advanced Therapy Medicinal Product Classification from European Medicines Agency for MB-107 Lentiviral Gene Therapy for X-Linked Severe Combined Immunodeficiency
April 19, 2020
Mustang Bio Reports Full-Year 2019 Financial Results and Recent Corporate Highlights
March 15, 2020
Mustang Bio Announces First Subject Treated in Phase 1/2 Trial with the Optimized CD20-targeted CAR T Cell Therapy MB-106
February 17, 2020